Table 3 Comparison of predicted and pathologic response in test set.
Case | Tumor reduction,% | Response, pathologic | Predicted response PCA cross validated by k-NN | Predicted response PLS-DA model 1 | Predicted response PLS-DA model 2 |
|---|---|---|---|---|---|
BC1843 | 0 | NC | NC | NC | PR |
BC1850 | 0 | NC | NC | NC | NC |
BC1862 | 0 | NC | NC | NC | PR |
BC1871 | 10 | NC | NC | NC | PR |
BC1869 | 100 | pCR | CR | CR | CR |
BC1864 | 100 | pCR | CR | CR | CR |
BC1421 | 100 | pCR | CR | CR | CR |
BC1870 | 100 | cCR | CR | CR | CR |
BC1861 | 40 | PR | PR | CR | CR |
BC1879 | 47 | PR | PR | NC | NC |
BC1866 | 40 | PR | PR | CR | CR |
BC1837 | 90 | PR | CR | CR | CR |
BC1838 | 80 | PR | PR | NC | NC |
BC1842 | 92 | PR | PR | PR | PR |
BC1834 | 0 | PR | PR | PR | CR |
BC1858 | 0 | PR | NC | NC | NC |
BC1880 | 40 | PR | PR | PR | PR |
BC1881 | 62 | PR | NC | PR | PR |
BC1849 | 22 | PR | NC | NC | PR |
BC1839 | 10 | PR | NC | NC | PR |
BC1513 | 33 | PR | PR | NC | PR |
BC1877 | 50 | PR | PR | NC | NC |
BC1853 | 0 | NC | NC | NC | NC |
BC1448 | 68 | PR | CR | CR | CR |
BC1134 | 5 | NC | NC | NC | NC |
BC1840 | 25 | PR | NC | NC | NC |
BC1848 | 85 | PR | CR | CR | CR |